Home Companies Catalysts Deep Dives
Kyprolis carfilzomib APPROVED
Drug Profile
ModalitySmall molecule
RouteIV
Therapy AreaOncology
Launch2012-07-20
Peak Sales Est$1600M
Formulations[{"id":"kyprolis-iv","doses":"20-56mg/m2","route":"IV","setting":"INFUSION_CENTER","frequency":"Days
Companies
AMGN (ORIGINATOR)100%
Mechanism: Proteasome inhibitor
Expert: Oral proteasome inhibitor targeting the 20S proteasome, inducing apoptosis in myeloma cells.
Everyday: Blocks cancer cells from disposing of damaged proteins, causing them to die.
Targets: ["PROTEASOME"]
Revenue History
PeriodRevenue ($M)
2024$1,503M
2025$1,412M
Programs (1)
IndicationStageKey StudyRegional Status
RRMMAPPROVEDASPIRE / ENDEAVOR[{"stage":"APPROVED","region":"US","approval_date":"2012-07-20"},{"stage":"APPRO
Notes
Declining -6%. Competitive pressure from newer MM therapies (bispecifics, CAR-T).
Data from Supabase · Updated 2026-03-24